BSE: 543346 | NSE: | Hospital & Healthcare Services | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Aashka Hospitals Ltd is a average quality company.
The key valuation ratios of Aashka Hospitals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Aashka Hospitals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 14.5% | 11.7% | 13.1% | 6.4% | 0.4% | 4.9% | - |
| Value Creation Index ⓘ | 0.0 | -0.2 | -0.1 | -0.5 | -1.0 | -0.7 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||
| Sales ⓘ | 27.7 | 27.2 | 40.7 | 39.7 | 18.9 | 22.9 | 23 |
| Sales YoY Gr. | - | -1.6% | 49.4% | -2.4% | -52.3% | 20.8% | - |
| Adj EPS ⓘ | 0.8 | 0.8 | 2.3 | 1 | -1.1 | 1 | 1 |
| YoY Gr. | - | -2.5% | 197.4% | -56.3% | -210% | NA | - |
| BVPS (₹) ⓘ | 9 | 13.5 | 16.3 | 41.3 | 40.2 | 41.2 | 41.2 |
| Adj Net Profit ⓘ | 1.4 | 1.4 | 4.1 | 2.3 | -2.6 | 2.4 | 2 |
| Cash Flow from Ops. ⓘ | 10.1 | -1 | 14.5 | -62.6 | 1 | 7.2 | - |
| Debt/CF from Ops. ⓘ | 3.3 | -32.2 | 1.9 | -0.5 | 29 | 2.8 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | -3.7% | -17.5% | 20.8% | ||||
| Adj EPS ⓘ | NA | 5% | -23.9% | NA | ||||
| BVPSⓘ | NA | 35.7% | 36.4% | 2.5% | ||||
| Share Price | - | - | 37.3% | 130.6% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 8.9 | 7 | 15.4 | 3.7 | -2.7 | 2.5 | 2.5 |
| Op. Profit Mgn % ⓘ | 34.4 | 31.6 | 24.5 | 21.6 | 1.9 | 20 | NAN |
| Net Profit Mgn % ⓘ | 4.9 | 5.1 | 10.1 | 5.9 | -13.6 | 10.3 | 10.3 |
| Debt to Equity ⓘ | 2.2 | 1.3 | 1 | 0.3 | 0.3 | 0.2 | - |
| Working Cap Days ⓘ | 0 | 119 | 109 | 424 | 1,532 | 1,242 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 28 | 29 | 37 | 104 | 49 | 0 |
Return on Equity has increased versus last 3 years average to 2.50%
Sales growth has been subdued in last 3 years -17.47%
Net Profit has been subdued in last 3 years -23.88%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 1 | - |
| TTM Sales (₹ Cr.) | 22.9 | - |
| BVPS (₹.) ⓘ | 41.2 | - |
| Reserves (₹ Cr.) ⓘ | 73 | - |
| P/BV ⓘ | 2.66 | - |
| PE ⓘ | 108.57 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 45.91 / 126.55 |
| All Time Low / High (₹) | 36.30 / 126.55 |
| Market Cap (₹ Cr.) | 256 |
| Equity (₹ Cr.) | 23.4 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 40.5 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|
| Sales | 28 | 27 | 41 | 40 | 19 | 23 |
| Operating Expenses ⓘ | 18 | 19 | 31 | 31 | 19 | 18 |
| Manufacturing Costs | 9 | 9 | 17 | 14 | 7 | 7 |
| Material Costs | 3 | 4 | 7 | 6 | 3 | 3 |
| Employee Cost | 4 | 4 | 5 | 5 | 3 | 3 |
| Other Costs ⓘ | 2 | 2 | 3 | 7 | 5 | 5 |
| Operating Profit ⓘ | 10 | 9 | 10 | 9 | 0 | 5 |
| Operating Profit Margin (%) | 34.4% | 31.6% | 24.5% | 21.6% | 1.9% | 20.0% |
| Other Income ⓘ | 0 | 0 | 0 | 0 | 3 | 4 |
| Interest ⓘ | 6 | 5 | 3 | 3 | 3 | 3 |
| Depreciation ⓘ | 3 | 3 | 3 | 3 | 3 | 3 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 1 | 1 | 4 | 3 | -3 | 3 |
| Tax ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 1 | 1 | 4 | 2 | -3 | 2 |
| PAT Margin (%) | 4.9% | 5.1% | 10.1% | 6.0% | -13.6% | 10.3% |
| Adjusted EPS (₹) | 0.8 | 0.8 | 2.3 | 1.0 | -1.1 | 1.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 15 | 24 | 29 | 97 | 94 | 96 | ||||
| Share Capital ⓘ | 17 | 18 | 18 | 23 | 23 | 23 | ||||
| Reserves ⓘ | -2 | 6 | 11 | 73 | 71 | 73 | ||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Debt | 26 | 27 | 22 | 23 | 22 | 14 | ||||
| Long Term Debt | 25 | 25 | 20 | 17 | 16 | 8 | ||||
| Short Term Debt | 1 | 2 | 2 | 6 | 6 | 6 | ||||
| Trade Payables | 3 | 2 | 4 | 2 | 3 | 2 | ||||
| Others Liabilities ⓘ | 11 | 6 | 10 | 8 | 10 | 9 | ||||
| Total Liabilities ⓘ | 54 | 60 | 65 | 129 | 128 | 121 | ||||
Fixed Assets | ||||||||||
| Gross Block | 56 | 56 | 64 | 66 | 66 | 66 | ||||
| Accumulated Depreciation | 9 | 12 | 14 | 17 | 20 | 23 | ||||
| Net Fixed Assetsⓘ | 46 | 44 | 49 | 48 | 45 | 43 | ||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Inventories | 0 | 1 | 1 | 1 | 0 | 0 | ||||
| Trade Receivables | 3 | 7 | 7 | 8 | 7 | 5 | ||||
| Cash Equivalents | 1 | 4 | 3 | 1 | 3 | 2 | ||||
| Others Assetsⓘ | 2 | 4 | 5 | 71 | 72 | 71 | ||||
| Total Assets ⓘ | 54 | 60 | 65 | 129 | 128 | 121 | ||||
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 10 | -1 | 15 | -63 | 1 | 7 |
| PBT ⓘ | 1 | 1 | 4 | 3 | -3 | 3 |
| Adjustment ⓘ | 8 | 7 | 6 | 6 | 3 | 2 |
| Changes in Working Capital ⓘ | 0 | -10 | 4 | -71 | 1 | 3 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ | 0 | 0 | -8 | -2 | 0 | -1 |
| Capex | 0 | 0 | -8 | -2 | 0 | -1 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | -9 | 4 | -8 | 63 | 1 | -8 |
| Net Proceeds from Shares ⓘ | 3 | 7 | 1 | 65 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -7 | 1 | -5 | -3 | -1 | -8 |
| Interest Paid ⓘ | -6 | -5 | -3 | -3 | -3 | -3 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 1 | 0 | 4 | 5 | 3 |
| Net Cash Flow ⓘ | 1 | 3 | -1 | -2 | 2 | -1 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 8.87 | 6.97 | 15.4 | 3.76 | -2.7 | 2.48 | ||||
| ROCE (%) | 14.54 | 11.72 | 13.12 | 6.38 | 0.42 | 4.89 | ||||
| Asset Turnover Ratio | 0.51 | 0.48 | 0.65 | 0.41 | 0.15 | 0.18 | ||||
| PAT to CFO Conversion(x) | 10 | -1 | 3.75 | -31.5 | N/A | 3.5 | Working Capital Days | |||
| Receivable Days | 46 | 68 | 63 | 70 | 141 | 93 | ||||
| Inventory Days | 6 | 7 | 5 | 5 | 9 | 6 | ||||
| Payable Days | 297 | 262 | 187 | 187 | 295 | 302 | ||||
The company is certified by National Accreditation Board for Hospitals and Healthcare Providers (NABH Accredited) for tertiary and apical care level hospital in Gujarat. It is an integrated healthcare service provider, committed to deliver quality healthcare services to its patients in modern facilities that includes prevention, best treatment and proper rehabilitation. The company decided to step-up its support in the fight against COVID-19 and was a designated COVID-19 treatment hospital. With the support of its doctors and staffs, it has treated more than 2000 COVID-19 patients. The company is a growing organization that aims at strengthening and establishing itself as the foremost healthcare services provider. It strives to serve with its ultra-modern medicinal practices and state of the art infrastructure for medical as well as surgical care solutions.
The company has a team of medical practitioners who ensures that patients get the quality healthcare services. Its dedicated team is trained to take care of the patients and handle all kinds of emergencies. Its healthcare staff members comprise of Medical Director, Quality Manager, Clinical pharmacist, Microbiologist, Medical Officers, Clinical Assistants, Infection Control Nurse, Nursing staff, Attendants, Technicians, Dietician/Nutritionist, Medical Transcriber, Biomedical Engineers. It is associated with Companies, Organization, University and Institute for providing regular healthcare check-up facilities to their employees and their Post-Graduation Students at affordable rates. It has entered into Memorandum of Understanding with Blood Banks like Shraddhadeep Blood Bank and Sanjivani Blood Bank (Vol.) and Apheresis Centre from whom it procure blood and blood components to the meet the needs of patients admitted at its hospital. Also, it has associations and affiliations with major Insurance Companies that processes insurance claims admissible under the Mediclaim policy for its patients.
Business area of the company
Aashka Hospital is an integrated healthcare service provider that offers the best quality of healthcare facilities including prevention, best treatment, and rehabilitation.
Awards, Accreditations or Recognition
Major Events
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
